A5008435049- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Venous Thromboembolism Diagnosis and Management
- Cancer-related gene regulation
- Hemostasis and retained surgical items
- Atrial Fibrillation Management and Outcomes
- Neonatal Respiratory Health Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Antiplatelet Therapy and Cardiovascular Diseases
- CAR-T cell therapy research
- Blood groups and transfusion
- Vascular Malformations and Hemangiomas
- Congenital Diaphragmatic Hernia Studies
- Vascular Malformations Diagnosis and Treatment
- Liver Disease and Transplantation
- Respiratory Support and Mechanisms
- Central Venous Catheters and Hemodialysis
- Chronic Lymphocytic Leukemia Research
- Vascular anomalies and interventions
- Inhalation and Respiratory Drug Delivery
- Neurogenetic and Muscular Disorders Research
Cliniques Universitaires Saint-Luc
2016-2025
UCLouvain
2015-2025
UCLouvain Saint-Louis Brussels
2004-2024
Canadian Hemophilia Society
2021-2024
University of Pennsylvania
2024
Ege University
2024
Pfizer (United States)
2024
Hemophilia Federation of America
2023
Finnish Red Cross
2023
Royal Free London NHS Foundation Trust
2023
Objective: To determine which venous malformations (VMs) are at risk for coagulopathy.Venous slow-flow vascular present birth, and localized intravascular coagulopathy (LIC) causes pain thrombosis within a lesion severe bleeding during surgical procedures.Design: Prospective convenience sample accrued from 2 multidisciplinary sites in Brussels, Belgium, Caen, France. Participants:The study population comprised 140 patients with clinical data coagulation parameters.Magnetic resonance imaging...
Moderate-to-severe hemophilia B is treated with lifelong, continuous coagulation factor IX replacement to prevent bleeding. Gene therapy for aims establish sustained activity, thereby protecting against bleeding without burdensome replacement.
The Hemophilia Joint Health Score (HJHS) was developed and validated to detect arthropathy in children. Additional evidence is required show validity adults. We studied the convergent discriminant construct of HJHS version 2.1(HJHSv2.1) adults with hemophilia. A secondary aim define age-related normative adult HJHSv2.1 reference values.
MYH9-related disease (MYH9-RD) is a rare autosomal-dominant disorder caused by mutations in the gene for nonmuscle myosin heavy chain IIA (NMMHC-IIA). MYH9-RD characterized considerable variability clinical evolution: patients present at birth with only thrombocytopenia, but some of them subsequently develop sensorineural deafness, cataract, and/or nephropathy often leading to end-stage renal (ESRD). We searched genotype-phenotype correlations largest series consecutive collected so far (255...
During the coronavirus disease 2019 (COVID-19) pandemic, several cases of chilblains have been reported.
Fidanacogene elaparvovec, an adeno-associated virus (AAV) gene-therapy vector for hemophilia B containing a high-activity human factor IX variant (FIX-R338L/FIX-Padua), was associated with sustained activity in phase 1-2a study.
Joint pain is common in haemophilia and may be acute or chronic. Effective management essential to reduce the burden that imposes on patients. However, choice of appropriate pain-relieving measures challenging, as there a complex interplay factors affecting perception. This can manifest differences patients' experiences response pain, which require an individualized approach management. Prophylaxis with factor replacement reduces likelihood bleeds bleed-related whereas on-demand therapy...
Introduction Haemophilia treatment varies significantly between individuals, countries and regions details of bleed rates, factor consumption injection frequency are often not available. Aim To provide an overview the FVIII / FIX practice outcome for patients with haemophilia A ( HA ) or B HB across Europe. Methods Non‐interventional, 12‐month retrospective study where anonymized data were retrieved from centres/registers in Belgium, France, Germany, Italy, Spain, Sweden United Kingdom. Male...